AbelZeta has regained global rights to dual CD19/CD20 CAR-T prizlon-cel and received FDA IND clearance, backed by early Chinese data reporting a 91.5% response rate.
AbelZeta's FDA-cleared Phase II C-CAR168 trial tests whether dual-target CAR-T can deliver durable renal responses in refractory lupus nephritis.
AbelZeta’s C-CAR031 study shows a 44.4% response rate in advanced liver cancer, but durability and resistance remain key tests.
AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.